Fortune crowns the bold before the worthy” ― Agona Apell
The S&P 500 has risen over 15% so far in 2019, one of its fastest starts to a year in decades. The Dow is near all-time highs despite being weighed down by the troubles at Boeing (BA).
Insider buying has ebbed significantly since hitting eight year highs in December. So which stocks are insiders still purchasing. Here are four interesting names insiders still seem to like despite the big rally in the market so far this year.
'10 Simple Rules To Trade Options Like A Pro' from our friends at Investors Alley is a good quick overview on using option strategies to mitigate risk and enhance returns in your portfolio. These strategies are well suited to high beta sectors like biotech where option premiums tend to be large. The report is now available free via download HERE
Let's start with Chaparral Energy (CHAP). This 'Busted IPO' from the energy sector is starting to pick up some considerable insider buying. A beneficial owner scarfed up over $4.5 million in new shares on April 2nd. The CEO also bought $40,000 in stock on March 29th. It should be noted that the same beneficial owner added over $4.5 million to his stake on March 20th.
The stock has not rewarded shareholders since coming public in May of 2017. The shares do look like they are trying to form a bottom in recent months. Three analyst firms have reiterated or assigned Buy ratings to the name over the past nine months - Johnson Rice ($31 price target), Stifel Nicolaus ($23 price target) and Imperial Capital ($10 price target).
The company's acreage is located in Woodford shale region of Oklahoma. The company has an approximate market cap of $250 million, is profitable and selling at approximately one time revenues.
Chaparral is not the only E&P concern seeing considerable insider activity. Gran Tierra Energy has a beneficial owner buy more than $1.2 million in new shares on April 1st and 2nd. The same beneficial owner added more than $7 million to their core stake throughout March in numerous transactions.
The shares have been range bound between the $2 and $4 levels for over four years now and currently go for right around $2.50 apiece. Gran Tierra is focused on energy production in South America and recently entered Ecuador. The stock gets sparse coverage on Wall Street despite a market capitalization just south of $1 billion.
Small oncology play AVEO Pharmaceuticals (AVEO) which has had a roller coaster ride over the past couple of years see beneficial owners buy most of a recent secondary offering. It appears several beneficial owners bought almost all of a capital raise on April 8th that raised some $25 million in proceeds.
The stock was crushed in late January after news broke that the company would not file a U.S. marketing application seeking approval for its compound FOTIVDA for the treatment of adult patients with advanced renal cell carcinoma as planned. AVEO will now wait until it has more mature overall survival (OS) data from its Phase 3 TIVO-3 study.
The stock got down to 50 cents a share in late March before buyout speculation perked up the shares. In early April, the stock rose further on early stage data evaluating the combination of FOTIVDA and cytarabine in patients with relapsed/refractory acute myeloid leukemia. Evidently insiders still believe the company has upside and remain patient investors in this very high beta name.
It has not been a good few months for shareholders in Walgreens Boots Alliance (WBA). The company has come under increasing scrutiny for tobacco sales, especially for youth sales by the FDA. Walgreens also could be impacted by various drug pricing legislation currently floating around.
More importantly, the company missed both top and bottom line expectations when it reported Q4 results early in April. Amazon (AMZN) also looks like it will be targeting the pharmacy space. At least one insider believes the shares have gotten oversold. The COO of the company bought just under a $1 million in new shares on April 3rd. It was the first insider purchase in the stock (after myriad sells) since mid July of 2018 when the CEO bought a much chunk of equity at just under $64.00 a share.
The stock advanced quickly to just over $85.00 a share after that insider buy before the company encountered its recent troubles. The equity is not expensive at roughly nine times earnings with a more than three percent dividend yield to boot.
And those are four names seeing significant insider buying at the moment.
Some of the best things that have ever happened to us wouldn’t have happened to us, if it weren’t for some of the worst things that have ever happened to us.” ― Mokokoma Mokhonoana
Thank You & Happy Hunting,
We published an extensive free report on a new 7% yielding stock I just added to my personal portfolio in late March. The shares have recent insider buying as well. If you are signed up to receive our free reports, you should have received this research automatically in your email. If you want this investment analysis and are not registered yet, just go to bretjenseninvests.com and hit the 'free reports' tab to download this latest report. This action will also register you for all the free reports we put out going forward as published as well.